ArticlePharmaceutical research2006
Dog colonoscopy model for predicting human colon absorption.
Article in Pharmaceutical research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 49 citations in OpenAlex.
- Application of New Approach Methodologies to Improve Oral Biopharmaceutic Assessments.Pharmaceutics · 2026Review
- Preliminary non-comparative evaluation of an adapted colonoscopy preparation protocol for dogs using sodium picosulphate and magnesium citrate.The Veterinary record · 2025Article
- Challenges in Permeability Assessment for Oral Drug Product Development.Pharmaceutics · 2023Review
- A Critical Overview of the Biological Effects of Excipients (Part II): Scientific Considerations and Tools for Oral Product Development.The AAPS journal · 2022Review
- Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.Molecular pharmaceutics · 2021Article
- Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat.Pharmaceutics · 2020Article
- Enterohepatic circulation of glucuronide metabolites of drugs in dog.Pharmacology research & perspectives · 2019Article
- Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.The AAPS journal · 2015Article
- Design of prodrugs to enhance colonic absorption by increasing lipophilicity and blocking ionization.Pharmaceuticals (Basel, Switzerland) · 2014Article
- Interdisciplinary science and the design of a single-dose antibiotic therapy.Pharmaceutical research · 2011Review
- The use of gastrointestinal intubation studies for controlled release development.British journal of clinical pharmacology · 2009Review
- Dog colonoscopy model for predicting human colon absorption.Pharmaceutical research · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was conducted to develop and validate a dog colon model that predicts colon permeability in humans.
methodsThe following compounds were studied: Class 1 highly soluble (HS)/highly permeable (HP): aminophylline, propranolol, CP-409092; Class 2 LS/HP: nifedipine; trovafloxacin, sertraline; Class 3 HS/LP: azithromycin, atenolol, CP-331684, CP-424391; Class 4 LS/LP: CJ-13610. Administration to dogs was made 30 cm cranial to the anal sphincter with a lubricated Schott Model VFS-5 flexible endoscope. The bioavailability of the compound following the colon administration in dogs, relative to the same formulation administered orally (relative bioavailability), was determined.
resultsExcept for atenolol, a small hydrophillic molecule, the relative bioavailability from administration to the colon of the dog correlated well with the following compound properties: high solubility and high, passive permeability > high solubility, low permeability > low solubility, high, passive permeability approximately low solubility, low permeability.
conclusionThe dog colon model is proposed as a surrogate for human intubation studies when the controlled release candidate falls in BCS Classes 2 (LS/HP), 3 (HS/LP), and 4 (LS/LP). However, no human intubation or dog colon studies are required for Class 1 (HS/HP), as these compounds are likely to be well absorbed from the colon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.